The global congenital adrenal hyperplasia treatment market size was valued at USD 416.93 Million in 2025 and is projected to grow from USD 444.32 Million in 2026 to USD 739.23 Million by 2034, registering a CAGR of 6.57% during the forecast period (2026–2034). North America dominated the congenital adrenal hyperplasia treatment market with a share of 45.17% in 2025.
Congenital adrenal hyperplasia (CAH) treatment refers to medical therapies used to manage hormone deficiencies and control excess androgen production caused by inherited adrenal enzyme disorders. Congenital adrenal hyperplasia treatments are commonly tracked under HSN Code 3004 (medicaments for therapeutic or prophylactic uses) and SIC Code 2834 (Pharmaceutical Preparations).
The congenital adrenal hyperplasia treatment market demand is driven by the need for effective hormone replacement, increasing diagnosis of CAH, and the development of therapies that improve treatment convenience and disease control. Healthcare providers are increasingly using glucocorticoids, mineralocorticoids, and CRF1 and ACTH pathway inhibitors to manage hormone levels and disease symptoms, contributing to congenital adrenal hyperplasia treatment market growth.
By Disease Type
By Drug Class
By Distribution Channel
Download a Free Sample To learn more about this report,
Shift toward Long-Acting Hormone Replacement Therapies
The congenital adrenal hyperplasia treatment market analysis shows a shift toward long-acting hormone replacement therapies designed to provide sustained hormone activity and reduce the frequency of medication administration. These therapies are being developed to maintain more consistent hormone levels and improve treatment management.
Use of Non-Steroidal Treatments for Congenital Adrenal Hyperplasia
The congenital adrenal hyperplasia treatment market is witnessing growth in non-steroidal treatments for congenital adrenal hyperplasia that target underlying hormonal pathways without relying solely on conventional corticosteroid replacement. Emerging approaches are being investigated to regulate excess androgen production and improve hormonal balance.
Supply chain disruptions are expected to have a moderate impact on the congenital adrenal hyperplasia treatment market share due to dependence on active pharmaceutical ingredients, hormone replacement medicines, specialty drugs, pharmaceutical manufacturing, and healthcare distribution networks. The market is expected to follow a stair-step recovery, as shortages of pharmaceutical ingredients, manufacturing delays, packaging constraints, and transportation disruptions can affect treatment availability in phases before production and distribution capacity stabilize. The market is expected to grow at a CAGR of 6.57%, but supply chain constraints could approximately lower this by 1.0 percentage point, resulting in short-term growth of around 5.57%. As supply conditions normalize through improved availability of pharmaceutical ingredients and hormone replacement therapies, stable manufacturing capacity, smoother distribution networks, and reliable healthcare supply, congenital adrenal hyperplasia treatment market growth is expected to gradually return to 6.57%.
The congenital adrenal hyperplasia treatment market forecasts strategic investment activity driven by targeted oral therapies, late-stage clinical development, expansion of rare endocrine disease portfolios, and acquisition of established CAH treatment assets.
Key Investment and Funding Activities in Congenital Adrenal Hyperplasia Treatment Market, 2026
Vertex Pharmaceuticals / Crinetics Pharmaceuticals
USD 10 Billion
In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for approximately USD 10 billion, gaining access to atumelnant, an investigational daily oral therapy in Phase 3 development for congenital adrenal hyperplasia.
Immedica Pharma
USD 65 Million
In January 2026, Immedica Pharma completed its acquisition of Neurocrine Group Limited for USD 65 million, including global rights to Alkindi and ex-US rights to Efmody, established therapies used in congenital adrenal hyperplasia.
Expansion of Novel Cortisol Replacement Therapies and Demand for Treatments with Improved Dosing Convenience Drives Market
The expansion of novel cortisol replacement therapies is increasing treatment options for patients with congenital adrenal hyperplasia. New approaches aim to provide more consistent hormone replacement and better control of cortisol levels.
The demand for treatments with improved dosing convenience is growing as patients seek simpler ways to manage long-term CAH therapy. Treatments with easier dosing schedules can reduce the burden of frequent medication use and support treatment adherence.
Risk of Adrenal Crisis from Inadequate Disease Management and Frequent Monitoring Requirements Restrains Market Expansion
The risk of adrenal crisis from inadequate disease management can create significant challenges for patients with congenital adrenal hyperplasia. Insufficient glucocorticoid replacement, missed doses, illness, or inadequate dose adjustments during physiological stress can increase the risk of adrenal crisis.
Frequent monitoring requirements during treatment can increase the burden associated with congenital adrenal hyperplasia management. Patients may require regular assessment of hormone levels, clinical symptoms, growth, blood pressure, and treatment response to maintain appropriate hormonal control.
Expansion of Congenital Adrenal Hyperplasia Treatment through Endocrine Care and Pediatric Patients Offers Growth Opportunities
The need for specialized management of congenital adrenal hyperplasia is creating opportunities for pharmaceutical companies and endocrine care providers to serve patients requiring long-term treatment. Improved hormone replacement options can support disease management across different patient groups. Revenue can be generated through therapies, specialist consultations, and treatment monitoring services, contributing to congenital adrenal hyperplasia treatment market growth.
The need for early and continuous management is creating opportunities for treatment providers to serve pediatric hospitals, endocrinology clinics, and families managing congenital adrenal hyperplasia. Revenue can be generated through medicines, follow-up consultations, and monitoring programs, supporting market growth.
The classic congenital adrenal hyperplasia segment is expected to grow at a CAGR of 6.81% during the forecast period, driven by the need for long-term hormone replacement and disease management.
The nonclassic congenital adrenal hyperplasia segment is expected to grow at a CAGR of 6.06% during the forecast period, supported by increasing diagnosis and treatment of patients with milder forms of CAH.
Request Customizationto receive a tailored report.
The glucocorticoids segment accounted for a share of 59.46% in 2025, owing to their established role in replacing deficient cortisol and controlling excess adrenal androgen production.
The CRF1 and ACTH pathway inhibitors segment is expected to grow at a CAGR of 9.48% during the forecast period, fueled by the development of therapies targeting hormonal pathways involved in adrenal androgen production.
The hospital pharmacies segment accounted for a share of 51.82% in 2025 due to the need for prescription-based hormone therapies and specialist supervision in CAH management.
The online pharmacies segment is expected to grow at a CAGR of 8.34% during the forecast period, supported by the adoption of digital prescription services and home delivery of medicines.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Supported by Clinical Trials
The North America congenital adrenal hyperplasia treatment market accounted for a share of 45.17% in 2025.
The United States congenital adrenal hyperplasia treatment market is supported by the Phase 2 pediatric clinical trial, which is evaluating crinecerfont in children younger than 4 years with classic CAH who are already receiving hydrocortisone treatment. The trial reflects continued development of treatment approaches that can be used alongside established hormone replacement therapy.
The Canada congenital adrenal hyperplasia treatment market is benefited by continued clinical development of new treatment approaches alongside conventional glucocorticoid therapy. Canada’s clinical trial registry is currently listing the CAHtalyst Pediatric Study, which is evaluating crinecerfont in pediatric patients with classic CAH.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Fueled by Advances in New Therapies and Treatment Pathways
The Asia Pacific congenital adrenal hyperplasia treatment market is expected to grow at a CAGR of 8.11% during the forecast period, making it the fastest-growing region.
The India congenital adrenal hyperplasia treatment market is supported by continued use of hydrocortisone and mineralocorticoid replacement therapy. Indian clinical guidance recommends early initiation of oral hydrocortisone and fludrocortisone for infants with classic CAH, followed by regular monitoring during childhood. This supports continued demand for hormone replacement treatment in pediatric CAH care.
The Japan congenital adrenal hyperplasia treatment market is shaped by advances in new therapies that can reduce dependence on conventional glucocorticoid treatment. The Phase 3 jRCT2031260194 trial is evaluating atumelnant in adults with classic CAH caused by 21 hydroxylase deficiency, with the treatment being assessed alongside glucocorticoid replacement to improve hormonal control. The trial reflects ongoing development of newer treatment approaches for CAH in Japan.
The China congenital adrenal hyperplasia treatment market is benefited by expanding early detection and treatment pathways for CAH. China’s newborn screening services continue to include CAH in several regions, with Chongqing’s current program screening newborns for CAH and providing follow up diagnosis and treatment for suspected cases.
Middle East & Africa: Market Growth Driven by Pediatric Endocrinology and Genetic Disorder Management
The Middle East & Africa congenital adrenal hyperplasia treatment market is expected to grow at a CAGR of 6.94% during the forecast period.
The UAE Ministry of Health and Prevention’s pediatric essential-medicines list includes hydrocortisone and fludrocortisone, which are used for hormone replacement in congenital adrenal hyperplasia. Congenital adrenal hyperplasia is also included among genetic diseases recognized under UAE Ministerial Decree No. 285.
The South Africa congenital adrenal hyperplasia treatment market is supported by national clinical guidelines that establish treatment pathways for patients with the disorder. The National Department of Health’s updated Paediatric Standard Treatment Guidelines recommend urgent referral of congenital adrenal hyperplasia cases and specialist-initiated glucocorticoid and mineralocorticoid replacement, including hydrocortisone and fludrocortisone.
Latin America: Market Growth Supported by Steroidogenesis and Rare Disease Management
The Latin America congenital adrenal hyperplasia treatment market is expected to grow at a CAGR of 6.66% during the forecast period.
The Mexican Social Security Institute (IMSS) clinical practice guideline for congenital adrenal hyperplasia due to 21-hydroxylase deficiency provides specific treatment recommendations, including hydrocortisone and fludrocortisone, with intravenous hydrocortisone protocols for adrenal crises. Mexico’s health authorities also use national clinical protocols to standardize diagnosis and treatment across public and private healthcare institutions.
Brazil’s National Neonatal Screening Program (PNTN) includes congenital adrenal hyperplasia in its newborn screening panel, with screening performed through 17-OHP testing during the first days of life. This supports earlier identification of CAH and timely initiation of treatment.
Europe: Market Growth Supported by Established National Guidelines for Hormone Replacement
The Europe congenital adrenal hyperplasia treatment market is expected to grow at a CAGR of 6.08% during the forecast period.
The United Kingdom congenital adrenal hyperplasia treatment market is supported by established national guidelines for hormone replacement and specialist management. NICE recommends glucocorticoid treatment for people with congenital adrenal hyperplasia, with hydrocortisone as the first-choice therapy and fludrocortisone when mineralocorticoid replacement is required. NICE also recommends stress-dose hydrocortisone and emergency management protocols for patients at risk of adrenal crisis.
The Germany congenital adrenal hyperplasia treatment market is shaped by continued management of 21-hydroxylase deficiency and adrenal insufficiency. The German Society for Pediatric Endocrinology and Diabetology has established clinical guidance for CAH caused by 21-hydroxylase deficiency, covering diagnosis, glucocorticoid treatment, and monitoring of affected patients.
The congenital adrenal hyperplasia treatment market competitive landscape is highly fragmented, with established pharmaceutical companies, biotechnology companies, endocrine disorder drug developers, and specialized hormone therapy providers. Key players such as Neurocrine Biosciences, Inc., Pfizer Inc., Johnson & Johnson, Sanofi S.A., and Teva Pharmaceutical Industries Ltd. are estimated to account for approximately 25–30% of the global congenital adrenal hyperplasia treatment market share.
Established players compete mainly through hormone replacement therapies, drug development, clinical research capabilities, therapeutic innovation, and treatment efficacy. Emerging and regional players in the congenital adrenal hyperplasia treatment market ecosystem focus on specialized therapies, novel hormone therapies, and application-specific endocrine disorder treatments.
June 2026: Neurocrine Biosciences presented two year data from the CAHtalyst Pediatric study showing sustained androgen control, reduced glucocorticoid exposure, and improved growth measures in children and adolescents with classic congenital adrenal hyperplasia.
May 2026: Neurocrine Biosciences reported two year pediatric data showing continued reductions in ACTH and 17-hydroxyprogesterone.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Tulathromycin Market Size, Share, Growth, Analysis, Report, 2034
Renal Replacement Therapy Market Size, Share, Growth, 2034
Advanced Cancer Pain Management Market Size, Share, 2034
Facial Injectable Market Size, Share, Growth, Forecast, 2034
Trigeminal Neuralgia (TN) Treatment Market Size, Share, 2034
Age Related Macular Degeneration Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com